• OPEN AN ACCOUNT
Indian Indices
Sensex
73,895.74 315.20
( 0.43%)
Global Indices
Nasdaq
51,839.66 468.68
(0.91%)
Dow Jones
7,763.25 38.12
(0.49%)
Hang Seng
66,308.10 794.11
(1.21%)
Nikkei 225
10,694.57 14.58
(0.14%)
Forex
USD-INR
95.89 0.16
(0.16%)
EUR-INR
109.08 -0.12
(-0.11%)
GBP-INR
126.82 -0.30
(-0.24%)
JPY-INR
0.60 0.00
(-0.20%)

EQUITY - MARKET SCREENER

Remus Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
78788
INE0O5T01011
276.4035981
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
REMUS
45.11
1114.77
EPS(TTM)
Face Value()
Div & Yield %
20.97
10
0.05
 

Aurobindo Pharma slides after USFDA issues 11 observations
Aug 17,2026
The facility, owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of Aurobindo Pharma, manufactures inhalers, dermatology and transdermal products. The USFDA had inspected the facility from 24 March 2025 to 10 April 2025 and issued Form 483 with 11 observations at the conclusion of the inspection.

The company has now received the Establishment Inspection Report (EIR), which classified the facility as “Voluntary Action Indicated” (VAI). The USFDA has concluded and closed the inspection.

With the facility receiving a VAI classification, pending applications for multiple inhalers and other dosage forms manufactured at the facility can now progress through the USFDA’s review process.

Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services.

The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.